Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,010.00
Bid: 2,006.00
Ask: 2,010.00
Change: 10.00 (0.50%)
Spread: 4.00 (0.199%)
Open: 2,008.00
High: 2,010.00
Low: 2,006.00
Prev. Close: 2,000.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hikma Pharmaceuticals Guides For Growth In 2016 As Profit Falls

Wed, 16th Mar 2016 07:24

LONDON (Alliance News) - Hikma Pharmaceuticals PLC on Wednesday reported a fall in pretax profit in 2015, but forecast a significant rise in revenue for the year ahead, helped by its recent acquisition of the Roxane Laboratories Inc, despite lowering its guidance for the Roxane business last month.

The company reported a pretax profit of USD318 million, down from USD362 million in 2014, as revenue slipped to USD1.44 billion from USD1.49 billion the year before.

Analysts had expected Hikma to report a pretax profit of USD302.2 million on revenue of USD1.44 billion, so it beat expectations for profit and met them for revenue.

The fall in revenue was primarily as a result of a decline in Hikma's Generics business due to increased competition, in line with the company's most recent guidance, which was down 30% to USD151 million in 2015 from USD216 million in 2014.

Hikma proposed a final dividend of 21 cents per share, taking its total dividend to 32 cents for the year, in line with what it paid in 2014.

Looking ahead, the company said it expects to see revenue in 2016 in the range of USD2.0 billion to USD2.1 billion at constant currency, driven by strong growth from all three of its business segments and boosted by ten months of revenue from the Roxane business.

This is despite expecting Roxane's full-year revenue in 2016 to be below USD650 million, although Hikma expects this to increase to USD700 million to USD750 million in 2017.

"The integration of the acquisition of Roxane, which closed at the end of February, will be a key focus this year and will transform our non-injectables business in the US, adding complementary and well differentiated products, an attractive pipeline, proven R&D capabilities and greater overall scale," said Chairman and Chief Executive Said Darwazah in a statement.

"From 2017, we expect the benefits from the investments that we have made in recent years - in R&D, M&A, co-development partnerships and licensing agreements - to accelerate. We have an exciting pipeline across our business segments that will drive accelerated and sustainable future growth," Darwazah added.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
4 Nov 2021 09:03

TOP NEWS: Hikma confirms 2021 guidance amid strong performance

TOP NEWS: Hikma confirms 2021 guidance amid strong performance

Read more
4 Nov 2021 07:58

Hikma reports solid trading in year to date

(Sharecast News) - Hikma Pharmaceuticals reiterated full-year guidance as the company reported solid trading across its business.

Read more
1 Nov 2021 13:52

Citi sees room for upside surprise on sales at Hikma Pharmaceuticals

(Sharecast News) - Analysts at Citi reiterated their 'buy' stance for shares of Hikma Pharmaceuticals ahead of the company's trading statement due out later in the same week.

Read more
28 Oct 2021 16:12

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
20 Oct 2021 09:51

LONDON BROKER RATINGS: BofA cuts Hammerson and upgrades Capco

LONDON BROKER RATINGS: BofA cuts Hammerson and upgrades Capco

Read more
27 Sep 2021 12:14

LONDON MARKET MIDDAY: Gains ebb; crunch time for US spending bills

LONDON MARKET MIDDAY: Gains ebb; crunch time for US spending bills

Read more
27 Sep 2021 09:31

LONDON BROKER RATINGS: Upgrades for Ferrexpo, Go-Ahead and Old Mutual

LONDON BROKER RATINGS: Upgrades for Ferrexpo, Go-Ahead and Old Mutual

Read more
27 Sep 2021 09:28

UPDATE 2-Energy stocks, banks lift FTSE 100; Rolls-Royce top performer

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* Rolls-Royce jumps on sales of Spain-based ITP, U.S. Air Force contract* Energy stocks track crude oil prices higher* Hikma Pharma gains o...

Read more
27 Sep 2021 08:50

LONDON MARKET OPEN: Rolls-Royce rises on US Air Force contract win

LONDON MARKET OPEN: Rolls-Royce rises on US Air Force contract win

Read more
27 Sep 2021 08:16

TOP NEWS: Hikma buys US injectables firm Custopharm for USD375 million

TOP NEWS: Hikma buys US injectables firm Custopharm for USD375 million

Read more
27 Sep 2021 07:49

LONDON MARKET PRE-OPEN: Rolls-Royce wins USD2.6 billion B-52 contract

LONDON MARKET PRE-OPEN: Rolls-Royce wins USD2.6 billion B-52 contract

Read more
27 Sep 2021 07:05

Hikma buys Custopharm for $375m

(Sharecast News) - Hikma Pharmaceuticals said it was buying US firm Custopharm from Water Street Healthcare Partners for $375m on a debt and cash-free basis, with a further $50m payable on meeting certain commercial milestones.

Read more
27 Sep 2021 07:05

Hikma buys Custopharm for $375m

(Sharecast News) - Hikma Pharmaceuticals said it was buying US firm Custopharm from Water Street Healthcare Partners for $375m on a debt and cash-free basis, with a further $50m payable on meeting certain commercial milestones.

Read more
13 Sep 2021 16:09

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

Read more
2 Sep 2021 09:38

LONDON BROKER RATINGS: JPMorgan downgrades Unilever and Coca-Cola HBC

LONDON BROKER RATINGS: JPMorgan downgrades Unilever and Coca-Cola HBC

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.